302 related articles for article (PubMed ID: 14752171)
1. Safety of anti-inflammatory treatment--new ways of thinking.
Brune K
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
[TBL] [Abstract][Full Text] [Related]
2. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Alvaro-Gracia JM
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i21-5. PubMed ID: 14752172
[TBL] [Abstract][Full Text] [Related]
3. Osteoarthritis therapy--are there still unmet needs?
Laufer S
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
[TBL] [Abstract][Full Text] [Related]
4. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
Gaddi A; Cicero AF; Pedro EJ
Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
[TBL] [Abstract][Full Text] [Related]
5. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with cyclooxygenase-2 inhibitors.
Lanas A
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
[TBL] [Abstract][Full Text] [Related]
7. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.
Celotti F; Durand T
Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558
[TBL] [Abstract][Full Text] [Related]
8. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
9. COX-2 inhibitors: new drugs for the management of pain and inflammation.
Hutchins V; Hutchins B
Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
[No Abstract] [Full Text] [Related]
10. [The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis].
Stańczyk J; Kowalski ML
Pol Merkur Lekarski; 2001 Nov; 11(65):438-43. PubMed ID: 11852819
[TBL] [Abstract][Full Text] [Related]
11. COX-LOX inhibition: current evidence for an emerging new therapy.
Skelly MM; Hawkey CJ
Int J Clin Pract; 2003 May; 57(4):301-4. PubMed ID: 12800462
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism of inhibition OF COX-2 and COX-3 in gastrointestinal damage induced by NSAID in rats ].
Laudanno OM; San Miguel P; Aramberry LJ; Cesolari JA
Acta Gastroenterol Latinoam; 2003; 33(4):183-5. PubMed ID: 14708469
[TBL] [Abstract][Full Text] [Related]
13. COX-2 specific inhibitors in NSAID-intolerant patients.
Picado P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):11-6. PubMed ID: 14552699
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
van der Bijl P; van der Bijl P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
[TBL] [Abstract][Full Text] [Related]
15. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.
de Gaetano G; Donati MB; Cerletti C
Trends Pharmacol Sci; 2003 May; 24(5):245-52. PubMed ID: 12767724
[TBL] [Abstract][Full Text] [Related]
16. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
Ulbrich H; Soehnlein O; Xie X; Eriksson EE; Lindbom L; Albrecht W; Laufer S; Dannhardt G
Biochem Pharmacol; 2005 Jul; 70(1):30-6. PubMed ID: 15894291
[TBL] [Abstract][Full Text] [Related]
17. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
18. Aspirin and NSAID sensitivity.
Stevenson DD
Immunol Allergy Clin North Am; 2004 Aug; 24(3):491-505, vii. PubMed ID: 15242723
[TBL] [Abstract][Full Text] [Related]
19. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
Monsuez JJ
Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
[TBL] [Abstract][Full Text] [Related]
20. [Is there a future for COX-2 inhibitors?].
Yodfat Y
Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
